Login
$NVNO
$5.95 -$0.22 (3.65%) Live

$NVNO SEC Filings

Filed On Filing
10 Nov 2026 SCHEDULE 13G/A
29 Oct 2026 DEFA14A
29 Oct 2026 Proxy statement: annual meeting on December 10, 2026

CEO pay $584K, down 50% · say-on-pay vote

29 Oct 2026 10-Q
15 Sep 2026 SCHEDULE 13D/A
14 Sep 2026 Form 4: Duhay Francis, Director

Sold 11 shares ($123)

11 Sep 2026 144
21 Aug 2026 S-3
14 Aug 2026 SCHEDULE 13G/A
30 Jul 2026 10-Q
14 Jul 2026 8-K: Regulation FD Disclosure

On July 14, 2026, enVVeno Medical Corporation (the “Company”) issued an investor presentation, which may be used by the Company, including at meetings with investors, analysts or others, in whole or in part and possibly with modification...

12 Jun 2026 Form 4: Duhay Francis, Director

Sold 140 shares ($1.44K)

11 Jun 2026 144
15 May 2026 SCHEDULE 13G/A
15 May 2026 SCHEDULE 13G/A
06 May 2026 10-Q
29 Apr 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal Trial

26 Mar 2026 S-8
26 Mar 2026 10-K
13 Mar 2026 Form 4: Duhay Francis, Director

Sold 140 shares ($1.61K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support